Bellerophon Therapeutics, Inc. (BLPH) Income Statement Analysis

See more : Lanzhou Huanghe Enterprise Co., Ltd (000929.SZ) Income Statement Analysis – Financial Results

Complete financial analysis of Bellerophon Therapeutics, Inc. (BLPH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellerophon Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Fine besteel. Co., Ltd. (133820.KS) Income Statement Analysis – Financial Results
Guangdong Shirongzhaoye Co., Ltd. (002016.SZ) Income Statement Analysis – Financial Results
Multi Spunindo Jaya Tbk. (MSJA.JK) Income Statement Analysis – Financial Results
Bangsaphan Barmill Public Company Limited (BSBM.BK) Income Statement Analysis – Financial Results
Azkoyen, S.A. (AZK.MC) Income Statement Analysis – Financial Results

Bellerophon Therapeutics, Inc. (BLPH)

Industry: Biotechnology

Sector: Healthcare

Website: https://bellerophon.com

About Bellerophon Therapeutics, Inc.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	65.00K	102.00K	147.00K	348.00K	362.00K	373.00K	400.00K	0.00	0.00	0.00	0.00
Gross Profit	-65.00K	-102.00K	-147.00K	-348.00K	-362.00K	-373.00K	-400.00K	0.00	0.00	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	16.36M	13.02M	17.89M	11.03M	20.26M	17.85M	16.65M	33.37M	45.98M	52.99M	38.73M
General & Administrative	6.02M	7.15M	8.39M	6.44M	7.62M	6.75M	7.11M	14.87M	0.00	9.01M	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	6.02M	7.15M	8.39M	6.44M	7.62M	6.75M	7.11M	14.87M	13.78M	9.01M	7.19M
Other Expenses	0.00	0.00	0.00	-674.00K	27.88M	24.60M	23.76M	48.24M	0.00	0.00	0.00
Operating Expenses	22.38M	20.16M	26.28M	17.47M	27.88M	24.60M	23.76M	46.57M	59.75M	62.00M	46.23M
Cost & Expenses	22.38M	20.16M	26.28M	17.47M	27.88M	24.60M	23.76M	46.57M	59.75M	62.00M	46.23M
Interest Income	0.00	0.00	0.00	0.00	378.00K	184.00K	95.00K	109.00K	79.00K	0.00	0.00
Interest Expense	135.00K	5.00K	250.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	65.00K	102.00K	147.00K	348.00K	362.00K	373.00K	400.00K	377.00K	388.00K	429.00K	85.00K
EBITDA	-22.18M	-20.16M	-26.71M	-14.72M	-2.26M	-54.45M	-23.85M	-46.08M	-59.37M	-61.57M	-46.14M
EBITDA Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-22.38M	-20.16M	-26.28M	-17.47M	-27.88M	-24.60M	-23.76M	-46.57M	-59.75M	-62.00M	-46.23M
Operating Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	136.00K	605.00K	-577.00K	2.41M	25.26M	-30.22M	-495.00K	402.00K	79.00K	0.00	0.00
Income Before Tax	-22.25M	-19.56M	-26.85M	-15.07M	-2.63M	-54.82M	-24.25M	-46.46M	-59.67M	-62.00M	-46.23M
Income Before Tax Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-2.42M	-1.80M	-2.13M	-1.80M	-5.44M	29.85M	-438.00K	1.18M	0.00	0.00	0.00
Net Income	-19.83M	-17.76M	-24.73M	-13.27M	2.81M	-54.82M	-23.81M	-46.46M	-59.67M	-62.00M	-46.23M
Net Income Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-2.08	-1.87	-3.17	-2.95	0.65	-21.11	-23.72	-56.81	-5.01	-4.80	-3.58
EPS Diluted	-2.08	-1.87	-3.17	-2.95	0.65	-21.11	-23.72	-56.81	-5.01	-4.80	-3.58
Weighted Avg Shares Out	9.55M	9.50M	7.80M	4.50M	4.34M	2.60M	1.00M	817.85K	11.91M	12.91M	12.91M
Weighted Avg Shares Out (Dil)	9.55M	9.50M	7.80M	4.50M	4.34M	2.60M	1.00M	817.85K	11.91M	12.91M	12.91M

Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?

July 25, 2023investorplace.com

Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice. The Listing Qualifications Department for the Nasdaq Exchange has decided to delist shares of BLPH stock come Friday unless it...

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH)

July 5, 2023benzinga.com

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails

June 6, 2023zacks.com

Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint.

Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?

June 6, 2023zacks.com

Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial

June 5, 2023marketwatch.com

Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study. The company said its INOpulse for...